Segment, Geographic and Other Revenue Information - Revenues by Products (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2025	Jun. 30, 2024	Jun. 29, 2025	Jun. 30, 2024
Revenue from External Customer [Line Items]
Revenues:		$ 14,653	$ 13,283	$ 28,367	$ 28,162
Alliance revenues		2,273	2,067	4,386	4,240
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		14,305	12,991	27,746	27,595
Biopharma [Member] | U.S. Commercial Division [Member]
Revenue from External Customer [Line Items]
Revenues:	[1]	8,793	7,828	17,078	17,254
Biopharma [Member] | International Commercial Division [Member]
Revenue from External Customer [Line Items]
Revenues:		5,512	5,163	10,668	10,341
Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues:	[2]	328	278	585	535
Pfizer Ignite [Member]
Revenue from External Customer [Line Items]
Revenues:		20	15	37	32
Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Alliance revenues		2,273	2,067	4,386	4,240
Royalty [Member]
Revenue from External Customer [Line Items]
Royalty revenue		426	345	734	608
Primary Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		5,540	4,952	11,236	12,163
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[3]	2,003	1,877	3,926	3,917
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,383	1,359	3,043	3,050
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		381	195	945	548
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[4]	427	251	918	2,286
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		359	356	607	533
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		143	56	274	201
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		109	100	172	165
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		736	759	1,350	1,463
Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		4,378	4,083	8,364	7,926
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,615	1,323	3,101	2,460
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		322	303	450	497
Specialty Care [Member] | Sulperazon (Outside the U.S. and Canada) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		166	144	330	311
Specialty Care [Member] | Zavicefta (Outside the U.S. and Canada) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		163	150	299	275
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		154	179	294	338
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		139	97	291	255
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		56	74	213	274
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		106	119	201	239
Specialty Care [Member] | Cresemba [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		111	71	184	146
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		69	47	127	89
Specialty Care [Member] | All other Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,087	1,146	2,170	2,221
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		390	429	705	821
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		4,387	3,956	8,145	7,505
Oncology [Member] | Ibrance [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		1,049	1,130	2,026	2,184
Oncology [Member] | Xtandi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[5]	566	495	1,023	913
Oncology [Member] | Padcev [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		542	394	967	735
Oncology [Member] | Oncology Biosimilars [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[6]	353	279	617	543
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		251	169	473	332
Oncology [Member] | Adcetris [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[7]	255	279	472	536
Oncology [Member] | Inlyta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		243	252	462	489
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:	[8]	182	148	317	264
Oncology [Member] | Bosulif [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		149	167	300	313
Oncology [Member] | Tukysa [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		132	121	234	227
Oncology [Member] | Aromasin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		111	87	219	170
Oncology [Member] | Elrexfio [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		85	22	145	35
Oncology [Member] | Talzenna [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		46	32	86	55
Oncology [Member] | Tivdak [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		46	33	79	60
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues:		$ 380	$ 347	$ 725	$ 648

[1] Refer to Note 13A above.

[2] PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.

[3] Reflects alliance revenues and product revenues.

[4] The amount for the first six months of 2024 included a $771 million favorable final adjustment to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023.

[5] Primarily reflects alliance revenues and royalty revenues.

[6] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Retacrit, Zirabev, Trazimera and Nivestym.

[7] Reflects product revenues and royalty revenues.

[8] Erbitux® is a registered trademark of ImClone LLC.